c353cc16-2e98-48ac-8416-49f1532466f7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- PROTEIN_SECRETION+0.500
- ANDROGEN_RESPONSE+0.400
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- MTORC1_SIGNALING+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- ADIPOGENESIS+0.300
- ALLOGRAFT_REJECTION+0.300
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.300
- ANGIOGENESIS-0.200
- COAGULATION-0.200
- APICAL_SURFACE-0.100
- APOPTOSIS-0.100
- BILE_ACID_METABOLISM-0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.100
- ESTROGEN_RESPONSE_LATE-0.100
- HEDGEHOG_SIGNALING-0.100
- P53_PATHWAY-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1200 | — | — | 0.872 |
| 2 | MNG533 | — | — | 0.840 |
| 3 | R190 | — | — | 0.831 |
| 4 | R427 | — | — | 0.825 |
| 5 | R315 | — | — | 0.823 |
| 6 | 4c67fdfb-4b74-46c4-9021-0b5317207db5 | — | — | 0.821 |
| 7 | 57AA1143-0FA1-4197-8CBE-517F6B885753 | — | — | 0.808 |
| 8 | TCGA-22-5492-01A-01R-1635-07 | — | cohortSQ1 | 0.808 |
| 9 | BS_2EN3X6HB | high-grade glioma | — | 0.802 |
| 10 | SRR934830 | — | — | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |